DiaSorin SpA
http://www.diasorin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DiaSorin SpA
Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Big Three Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Company Information
- Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
-
- Biotrin International
- DiaSorin Molecuular
- Focus Diagnostics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice